MX2010005966A - Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7). - Google Patents
Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7).Info
- Publication number
- MX2010005966A MX2010005966A MX2010005966A MX2010005966A MX2010005966A MX 2010005966 A MX2010005966 A MX 2010005966A MX 2010005966 A MX2010005966 A MX 2010005966A MX 2010005966 A MX2010005966 A MX 2010005966A MX 2010005966 A MX2010005966 A MX 2010005966A
- Authority
- MX
- Mexico
- Prior art keywords
- ptk7
- tirosina
- cinasa
- molecula
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Botany (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US503407P | 2007-11-30 | 2007-11-30 | |
| PCT/US2008/084949 WO2009073546A2 (en) | 2007-11-30 | 2008-11-26 | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010005966A true MX2010005966A (es) | 2010-06-15 |
Family
ID=40718460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010005966A MX2010005966A (es) | 2007-11-30 | 2008-11-26 | Conjugados de anticuerpo monoclonal-molecula asociada dirigidos a la proteina tirosina-cinasa 7 (ptk7). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120027782A1 (enExample) |
| EP (1) | EP2229187A2 (enExample) |
| JP (1) | JP2011505146A (enExample) |
| KR (1) | KR20100101124A (enExample) |
| CN (1) | CN101939028A (enExample) |
| AR (1) | AR069903A1 (enExample) |
| AU (1) | AU2008334076A1 (enExample) |
| CL (1) | CL2008003527A1 (enExample) |
| MX (1) | MX2010005966A (enExample) |
| TW (1) | TW200938223A (enExample) |
| WO (1) | WO2009073546A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ569236A (en) | 2005-12-08 | 2012-06-29 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| HUE035798T2 (en) | 2008-11-03 | 2018-05-28 | Syntarga Bv | CC-1065 analogues and conjugates |
| NO3056203T3 (enExample) | 2010-04-21 | 2018-05-12 | ||
| EP2380909A1 (en) * | 2010-04-26 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | PTK-7 protein involved in breast cancer |
| SA112330278B1 (ar) * | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| US8852599B2 (en) | 2011-05-26 | 2014-10-07 | Bristol-Myers Squibb Company | Immunoconjugates, compositions for making them, and methods of making and use |
| US20140323402A1 (en) * | 2011-08-12 | 2014-10-30 | Ascendis Phama A/S | Protein Carrier-Linked Prodrugs |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN105813653B (zh) | 2013-12-19 | 2020-06-26 | 西雅图基因公司 | 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物 |
| TR201810856T4 (tr) | 2014-01-10 | 2018-08-27 | Synthon Biopharmaceuticals Bv | CYS'le bağlı antikor-ilaç konjugatlarını saflaştırmak için usul. |
| SMT202100146T1 (it) | 2014-04-30 | 2021-05-07 | Pfizer | Coniugati di anticorpo anti-ptk7-farmaco |
| PL3151921T3 (pl) | 2014-06-06 | 2020-02-28 | Bristol-Myers Squibb Company | Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| ES2826566T3 (es) | 2014-11-21 | 2021-05-18 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas |
| AR103268A1 (es) | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| MX2018006072A (es) | 2015-11-19 | 2018-08-01 | Squibb Bristol Myers Co | Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos. |
| AU2017228470A1 (en) | 2016-03-04 | 2018-08-30 | Bristol-Myers Squibb Company | Combination therapy with anti-CD73 antibodies |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| WO2018213297A1 (en) | 2017-05-16 | 2018-11-22 | Bristol-Myers Squibb Company | Treatment of cancer with anti-gitr agonist antibodies |
| MX2019013132A (es) | 2017-05-25 | 2020-01-27 | Bristol Myers Squibb Co | Anticuerpos que comprenden regiones constantes pesadas modificadas. |
| EP3876998A1 (en) | 2018-11-05 | 2021-09-15 | Synaffix B.V. | Antibody-conjugates for targeting of tumours expressing trop-2 |
| CN110845480B (zh) * | 2019-11-22 | 2022-03-15 | 荣昌生物制药(烟台)股份有限公司 | 一种双功能细胞毒素及其用途 |
| US12605433B2 (en) | 2020-07-16 | 2026-04-21 | Uif (University Industry Foundation), Yonsei University | Antibody specifically binding to PTK7 and use thereof |
| CN115894696A (zh) * | 2021-08-18 | 2023-04-04 | 和迈生物科技有限公司 | 抗ptk7单域抗体及其应用 |
| IL315366A (en) | 2022-03-23 | 2024-11-01 | Synaffix Bv | Antibody pairs for targeting PTK7-expressing tumors |
| GB202212077D0 (en) | 2022-08-18 | 2022-10-05 | Tribune Therapeutics Ab | Agents that inhibit ccn ligand-induced signalling for treating disease |
| US20260078201A1 (en) * | 2022-09-06 | 2026-03-19 | Uif (University Industry Foundation), Yonsei University | Anti-ptk7 antibody, and use thereof |
| CN118852442A (zh) * | 2023-04-26 | 2024-10-29 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| WO2025040588A1 (en) * | 2023-08-18 | 2025-02-27 | Oncoinvent As | Monoclonal anti-ptk7 antibodies and derivatives |
| AR133955A1 (es) * | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1423110A4 (en) * | 2001-09-07 | 2005-04-27 | Scripps Research Inst | CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES |
| GB0219776D0 (en) * | 2002-08-24 | 2002-10-02 | Oxford Glycosciences Uk Ltd | A protein involved in carcinoma |
| US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
| BRPI0510909A2 (pt) * | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
| EA016577B1 (ru) * | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Конъюгаты антитело-лекарство и их применение |
| NZ569236A (en) * | 2005-12-08 | 2012-06-29 | Medarex Inc | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and their use |
-
2008
- 2008-11-26 EP EP08857264A patent/EP2229187A2/en not_active Withdrawn
- 2008-11-26 CL CL2008003527A patent/CL2008003527A1/es unknown
- 2008-11-26 AU AU2008334076A patent/AU2008334076A1/en not_active Abandoned
- 2008-11-26 MX MX2010005966A patent/MX2010005966A/es not_active Application Discontinuation
- 2008-11-26 WO PCT/US2008/084949 patent/WO2009073546A2/en not_active Ceased
- 2008-11-26 KR KR1020107014503A patent/KR20100101124A/ko not_active Withdrawn
- 2008-11-26 TW TW097145713A patent/TW200938223A/zh unknown
- 2008-11-26 JP JP2010536185A patent/JP2011505146A/ja not_active Withdrawn
- 2008-11-26 AR ARP080105143A patent/AR069903A1/es not_active Application Discontinuation
- 2008-11-26 CN CN200880118641XA patent/CN101939028A/zh active Pending
- 2008-11-26 US US12/745,503 patent/US20120027782A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2229187A2 (en) | 2010-09-22 |
| KR20100101124A (ko) | 2010-09-16 |
| CN101939028A (zh) | 2011-01-05 |
| JP2011505146A (ja) | 2011-02-24 |
| AU2008334076A1 (en) | 2009-06-11 |
| US20120027782A1 (en) | 2012-02-02 |
| AR069903A1 (es) | 2010-03-03 |
| WO2009073546A3 (en) | 2009-12-30 |
| TW200938223A (en) | 2009-09-16 |
| CL2008003527A1 (es) | 2009-10-09 |
| WO2009073546A2 (en) | 2009-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009073546A3 (en) | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7) | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| IL258880A (en) | Diarylhydantoin compounds | |
| MY163480A (en) | Sclerostin binding agents | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| EA200700321A1 (ru) | Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы | |
| MX348432B (es) | Epitopes. | |
| EA200971056A1 (ru) | ПРОДУЦИРОВАНИЕ РЕКОМБИНАНТНЫХ БЕЛКОВ В КЛЕТКАХ ПТИЦ Еbx® | |
| EA200601670A1 (ru) | Конъюгаты гидроксиалкилкрахмала и белка | |
| WO2005062977A3 (en) | Prostate cancer specific internalizing human antibodies | |
| WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
| UA87153C2 (ru) | Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы | |
| WO2010002862A3 (en) | Fibroblast growth factor receptor 3 (fgfr3) binding proteins | |
| MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
| WO2003100033A3 (en) | ANTI-αvβ6 ANTIBODIES | |
| EP2010911A4 (en) | TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS | |
| AU2006226733A8 (en) | Antibodies against CD38 for treatment of multiple myeloma | |
| UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
| EP2631248A3 (en) | Treatment of tumors using specific anti-L1 antibody | |
| SG10201803982TA (en) | Antibodies and processes for preparing the same | |
| TW200630381A (en) | Tumor endothelial marker-1 (TEM1) binding antibodies and uses thereof | |
| WO2010034006A3 (en) | The putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2. | |
| WO2008107471A3 (en) | Modified hydroxypolymer conjugates with killing effect on tumor cells | |
| BR9611947A (pt) | Isoindolonas fundidas como inibidores da quinase da proteina c | |
| WO2007076465A3 (en) | Cln248 antibody compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |